Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 10/20 | 0.57 |
| ▸ | CTSB | P07858 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390555 | 1.00 | ATM (0.62) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL1094506 | 1.00 | ATM (0.62) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL9929938 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL19924528 | 0.92 | ATM (0.54) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL598263 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL8523201 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL2736190 | 0.91 | ATM (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL12137049 | 0.91 | ATM (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL20204705 | 0.90 | CTSS (0.65) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL22962275 | 0.90 | CTSS (0.65) | ATMCTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | claimed |
| US-5977371-A | Tandem asymmetric transformation process | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0670305-B1 | PROCESS FOR PRODUCING 3-AMINO-2-HYDROXY-1-PROPANOL DERIVATIVE | KANEKA CORP (JP) | 1998-05-20 | — | — | EP | claimed |
| US-5744630-A | Method of producing 3-amino-2-hydroxy-1-propanol derivatives | KANEKA CORPORATION (JP) | 1998-04-28 | — | — | US | claimed |
| EP-0670305-A1 | PROCESS FOR PRODUCING 3-AMINO-2-HYDROXY-1-PROPANOL DERIVATIVE | KANEKA CORPORATION (JP) | 1995-09-06 | — | — | EP | claimed |
| US-4978744-A | Synthesis of dolastatin 10 | ARIZONA BOARD OF REGENTS (US) | 1990-12-18 | — | — | US | claimed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| CN-118530145-A | Synthesis method of darunavir key intermediate | 江苏八巨药业有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| EP-0184855-A2 | Resin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-06-18 | — | — | EP | disclosed |
| US-4591648-A | Histidine protection | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-05-27 | — | — | US | disclosed |
| EP-0172347-A2 | Renin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0017536-B1 | PROCESS FOR THE PREPARATION OF SOMATOSTATINE | SANOFI S.A. (FR) | 1983-03-23 | — | — | EP | disclosed |
| US-4337194-A | MULTISTEP, WITH PURIFICATION BY WASHING AFTER EACH COUPLING | C. M. INDUSTRIES (FR) | 1982-06-29 | — | — | US | disclosed |
| EP-0017536-A2 | Process for the preparation of somatostatine | SANOFI S.A. (FR) | 1980-10-15 | — | — | EP | disclosed |
| US-3975367-A | PEPTIDE, VIRICIDE, IMMUNOSUPPRESSANT, NEOPLASTIC CELLS | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | ATM 523/4885CTSK 3934/4885CTSB 3950/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | ATM 523/4885CTSK 3934/4885CTSB 3950/4885 |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | CTRL, SERPINB1, PRSS1 | ATM 3898/4885CTSK 41/4885CTSB 28/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | ATM 523/4885CTSK 3934/4885CTSB 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.